Open AccessCorrelation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients
Author(s) -
Rabia Doğukan,
Ramazan Uçak,
Fatih Mert Doğukan,
Canan Tanık,
Bülent Çıtgez,
Fevziye Kabukçuoğlu
Publication year - 2019
Publication title -
meme sağlığı dergisi/meme sağlığı dergisi
Language(s) - English
Resource type - Journals
eISSN - 1306-0953
pISSN - 1306-0945
DOI - 10.5152/ejbh.2019.4912
Subject(s) - triple negative breast cancer , medicine , immunohistochemistry , tumor microenvironment , breast cancer , estrogen receptor , progesterone receptor , oncology , cancer research , cancer , pathology
Triple-negative breast cancer (TNBC) is a heterogenous group of tumors with no estrogen receptor (ER), progesterone receptor (PR) and Cerb-B2/HER2 expression. Programmed death ligand-1 (PD-L1) is a transmembrane protein located on both non-tumor and tumor cells and it has been shown to be associated with the escape of tumor cells from the immune system. PD-L1-targeted therapy alone or in combination is now an alternative strategy in several aggressive tumor types. In this respect, TNBC is a potential candidate having limited treatment options and poor outcome.